About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

MMA Embolization for Refractory Chronic Migraine | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT06735833

MMA Embolization for Refractory Chronic Migraine

This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the tr...

Lead sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.•9 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Study Contact

CONTACT

[email protected]

Sponsors

Lead Sponsor

Cerenovus, Part of DePuy Synthes Products, Inc.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patient is between 18 and 65 years of age (inclusive) at the time of consent.
•2. Age of onset of Chronic Migraine ≤ 64 years.
•3. Age of onset of migraine diagnosis \< 50 years.
•4. Patient has a current diagnosis of refractory migraine.
•5. Patient has a current diagnosis of Chronic migraine.

Exclusion Criteria

•1\. Patients with a history for the last 2 years of other types of headache. 2. Patients with diagnosis of hemiplegic migraine or migrainous infarct. 5. Patients with current regular use of Opioids, Cannabis, Medical Marijuana, etc.
•6\. Women who are pregnant, lactating, or who are of childbearing age. 7. Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Patients in observational, natural history, and/or epidemiological studies not involving intervention are eligible. Sponsor approval is required.

Related studies

RECRUITINGPhase 3

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505 · Chronic Migraine

RECRUITINGPhase 3

Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

NCT06241313 · Migraine

RECRUITINGPhase 3

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713 · Chronic Migraine

A Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine

NCT07454798 · Migraine, Headache Disorders, Primary

New Methods for Evaluating Preventive Migraine Treatment

NCT07071506 · Migraine, Migraine With or Without Aura, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 17, 2026Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment70

Start dateApr 2025

Last updatedApr 17, 2026

Condition

Locations shown

Barrow Neurological Institute at St. Joseph's Hospital

Phoenix, Arizona

John Muir Physician Network Clin. Research Center

Walnut Creek, California

Hartford Hospital

Hartford, Connecticut

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 17, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions